Skip to content

Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula

A Randomized Trail Of Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula After Laparoscopic Distal Pancreatectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02790333
Enrollment
94
Registered
2016-06-03
Start date
2016-05-31
Completion date
2018-12-01
Last updated
2021-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Fistula, Pancreatic Neoplasms

Brief summary

The purpose of this trial is to establish an objective criterion for assessing pancreatic stump texture, and unify stapler cartridge according to pancreatic stump texture and thickness.

Detailed description

Distal pancreatectomy (DP) is the standard treatment for symptomatic benign, premalignant, and malignant lesions in the pancreatic body and tail.Laparoscopic distal pancreatectomy (LDP) are reported to have lower blood loss, fewer postoperative complications and a shorter length of stay without a substantial increase in the operative time. Pancreatic fistula (PF) is the major source of postoperative morbidity and is associated with numerous further complications, suffering, longer hospital stay, higher costs and sometimes death. Frequencies range from 5% to 64%. Several procedures have been proposed to reduce the rate of PF. stapler closure is considered to be safe and approved particularly in LDP. Numerous predictive factors for PF have been reported in previous studies. Among these risk factors, the most important might be the texture and thickness of the remnant pancreas. However, the judgment of pancreatic texture has been based on the surgeon's observation and there still exists no objective method of assessing pancreatic texture. Furthermore there is no strict guideline on which type of cartridge to use according to pancreatic stump texture and thickness. Therefore, this single blind randomized controlled trial is designed to establish an objective criterion for assessing pancreatic stump texture, and unify stapler cartridge according to pancreatic stump texture and thickness. Patients were stratified intraoperatively by gland texture-hard (fibrotic) or soft (normal) and subsequently randomized according to different stapler cartridge. Pancreatic fibrosis is accessed by histopathology and pancreatic stellate cell.

Interventions

PROCEDUREtraditional reloads

Blue cartridge with3.0mm height staple was used for pancreatic stump

PROCEDURETri-Staple reloads

Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump

Sponsors

Yi-Ping Mou
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. disease of pancreatic body and tail 2. Age: 18 years or older 3. distant metastases are not diagnosed preoperatively. 4. Patients who can provide written informed consent

Exclusion criteria

1. Patients with severe organ disease such as cardiac disease,respiratory illness 2. Patients with pancreaticojejunostomy,pancreatogastrostomy 3. Patients with conversion to laparotomy 4. Patients with pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Incidence of pancreatic fistula grade A/ B/C defined by ISGPF classificationThirty days after operationPancreatic amylase concentration in any post operative drains. Fistula is diagnosed if pancreatic amylase \> 3 times the upper normal limit of pancreatic amylase in plasma on post operative day 3 or later
Pancreatic fibrosis accessed by histopathology and pancreatic stellate cellintraoperative

Secondary

MeasureTime frame
Time to oral intakeDuration of hospital stay
MorbidityThirty days after operation
Readmission rateThirty days after operation
Postoperative hospital stayDuration of hospital stay
MortalityThirty days after operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026